Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 25 tags : Liver save search
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-
Published: 2021-06-25 (Crawled : 16:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
diabetes liver efruxifermin
Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH
Published: 2021-06-25 (Crawled : 16:00) - akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
treatment nash liver efruxifermin trial
Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021
Published: 2021-06-25 (Crawled : 16:00) - globenewswire.com
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 0.63%
H: 1.02%
C: -0.96%
presentation ongoing positive phase 3 liver trial
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients
Published: 2021-06-25 (Crawled : 16:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
diabetes nash liver efruxifermin
Global Ride Sharing Market Report 2021-2026: New Business Models to Cover Losses in Ride Sharing Business / Food & Freight Delivery / Micro-Mobility / Emergence of Autonomous Ride Sharing
Published: 2021-06-25 (Crawled : 13:15) - prnewswire.com
UBER M 1 d | $69.2 -2.95% -0.19% 23M
|
Technology Services
|
| O: 0.71%
H: 1.27%
C: 1.07%
autonomous food liver merge
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.52%
H: 1.36%
C: -7.74%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.26%
H: 1.5%
C: 0.72%
hepatitis ongoing biotech technology iot liver trial injection infections chronic hepatitis b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.